New smart drug takes aim at Hard-to-Treat brain cancers

NCT ID NCT07268053

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing an investigational drug called risvutatug rezetecan in 15 people with recurrent glioblastoma or brain metastases. The drug is designed to seek out and deliver a cancer-killing payload to tumor cells. The study first measures how much drug gets into the tumor during surgery, then offers additional doses to those who show a good response, while closely monitoring safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
risvutatug rezetecan (a targeted antibody-drug conjugate)
What this could lead to
If it works, this could point toward a new treatment option for aggressive brain tumors that have come back after standard therapy.
What could go wrong
This is a very early, small study (15 people) focused on safety and drug levels, not yet testing if it truly helps patients. The drug may not reach all tumor cells or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • St. Joseph's Hospital and Medical Center

    RECRUITING

    Phoenix, Arizona, 85013, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.